Form 4: Forte Biosciences CEO Paul Wagner Reports Stock Transactions
SEC Form 4 Filing
Paul A. Wagner, CEO of Forte Biosciences, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.
Summary
- On April 1, 2024, Paul A. Wagner, CEO of Forte Biosciences, reported transactions involving the company's common stock.
- 31,250 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Forte Biosciences common stock.
- Following the vesting, 2,453 shares were disposed of at a price of $0.7075 to satisfy tax obligations.
- After these transactions, Wagner directly owns 1,879,174 shares of Forte Biosciences common stock and 343,750 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | First Quarterly Vesting Date for RSUs |
| 04/01/2024 | Date of RSU vesting and stock disposition |
| 04/02/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.